Avadel Pharmaceuticals plc (AVDL)
21.64
+0.01 (0.05%)
Inactive · Last trade price on Feb 11, 2026
Avadel Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 279.14 | 169.12 | 27.96 | - | - | |
Revenue Growth | 65.06% | 504.79% | 25.20% | - | - |
Cost of Revenue | 15.82 | 15.28 | 0.85 | - | - |
Gross Profit | 263.32 | 153.84 | 27.12 | - | - |
Selling, General & Admin | 208.44 | 181.04 | 151.71 | 74.52 | 68.5 |
Research & Development | 42.02 | 15.2 | 13.26 | 20.7 | 17.1 |
Operating Expenses | 250.45 | 196.24 | 164.97 | 95.22 | 85.6 |
Operating Income | 12.87 | -42.4 | -137.85 | -95.22 | -85.6 |
Interest Expense | -9.31 | -10.83 | -9.89 | -12.34 | -9.94 |
Interest & Investment Income | 3.01 | 2.53 | - | - | 2.44 |
Other Non Operating Income (Expenses) | -1.63 | - | 1.89 | 1.22 | - |
EBT Excluding Unusual Items | 4.94 | -50.7 | -145.85 | -106.34 | -93.1 |
Merger & Restructuring Charges | - | - | - | -3.35 | 0.05 |
Gain (Loss) on Sale of Investments | 0.5 | 1.63 | -1.8 | -1.75 | -0.1 |
Legal Settlements | 57.34 | - | - | - | - |
Other Unusual Items | - | - | -13.13 | - | - |
Pretax Income | 62.78 | -49.08 | -160.78 | -111.44 | -93.15 |
Income Tax Expense | -1.89 | -0.25 | -0.5 | 26.03 | -15.82 |
Net Income | 64.67 | -48.83 | -160.28 | -137.46 | -77.33 |
Net Income to Common | 64.67 | -48.83 | -160.28 | -137.46 | -77.33 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 97 | 95 | 80 | 60 | 59 |
Shares Outstanding (Diluted) | 101 | 95 | 80 | 60 | 59 |
Shares Change | 6.19% | 18.67% | 33.41% | 2.66% | 6.54% |
EPS (Basic) | 0.67 | -0.51 | -2.00 | -2.29 | -1.32 |
EPS (Diluted) | 0.64 | -0.51 | -2.00 | -2.29 | -1.32 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 97.43 | -46.91 | -128.51 | -71.02 | -77.34 |
Free Cash Flow Per Share | 0.96 | -0.49 | -1.60 | -1.18 | -1.32 |
Gross Margin | 94.33% | 90.97% | 96.97% | - | - |
Operating Margin | 4.61% | -25.07% | -492.97% | - | - |
Profit Margin | 23.17% | -28.88% | -573.17% | - | - |
Free Cash Flow Margin | 34.90% | -27.74% | -459.57% | - | - |
EBITDA | 16.88 | -39.72 | -136.08 | -93.72 | -84.78 |
EBITDA Margin | 6.05% | -23.48% | - | - | - |
D&A For EBITDA | 4.01 | 2.68 | 1.77 | 1.49 | 0.82 |
EBIT | 12.87 | -42.4 | -137.85 | -95.22 | -85.6 |
EBIT Margin | 4.61% | -25.07% | - | - | - |